ASCO 2024: The Role of ctDNA in the TheraP Trial - LuPSMA vs Cabazitaxel in CRPC

By The Uromigos - Last Updated: July 10, 2024

Dr. Alex Wyatt from Vancouver Prostate Centre describes the predictive capabilities of ctDNA in determining outcomes in the TheraP trial.

Post Tags:Uromigos-ASCO
Advertisement

Related Podcasts

Episode 342: ESMO 2024 Preview with Silke Gillessen
Uromigos-ESMO
Episode 341: Hormone Resistance in Prostate Cancer
Uromigos-Prostate Cancer
Episode 340: Cancer Immunity Cycle Update
uromigo
Episode 339: Tres Uramigas Discuss ESMO Guidelines for GU
Uromigos-Bladder Cancer
Episode 338: RCC - Debulking Nephrectomy, The Future of Adjuvant Therapy, and More
Uromigos-Kidney Cancer
Advertisement
Advertisement

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Contributors and Partners

    Editorial Policy

    Advertising

    Connect

    eNewsletters

    Calendar

    Contact Us

    Contribute

    Our Network

    MashupMD

    Cancer Nursing Today

    Urban Health Today

    Blood Cancers Today

    DocWire News

    © 2024 Mashup Media, LLC. All rights reserved.

    Terms of Use | Privacy Policy